Tysabri and PML: What Symptoms Should You Discuss With Your Doctor?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Targeted Risk Management

If you or a loved one is taking Tysabri, recognizing the early symptoms of progressive multifocal leukoencephalopathy (PML) can be critical for timely intervention. Over decades of pharmacovigilance, researchers have identified a consistent pattern of neurological signs that warrant immediate discussion with a clinician. This page outlines the key symptoms and risk factors associated with Tysabri-related PML.

Understanding Tysabri and PML Risk

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and three factors are known to increase the risk in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML includes progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. The FDA Adverse Event Reporting System (FAERS) lists fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and depression among the most frequently reported adverse events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly confirm PML, they reflect the spectrum of neurological symptoms that may overlap with PML presentation.

Mechanism of PML and Legal Implications in Arizona

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion of immune cells to endothelial surfaces, preventing their migration into the central nervous system. This reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JCV, allowing the virus to reactivate and cause lytic infection of oligodendrocytes. The resulting demyelination leads to the clinical syndrome of PML. The latency between Tysabri exposure and PML onset can range from months to several years, with risk increasing after two years of continuous therapy. For patients in Arizona who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a claim. In Arizona, the statute of limitations for personal injury actions generally is two years from the date the injury is discovered or reasonably should have been discovered. For product liability claims involving prescription drugs, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Tysabri caused their PML. Given that PML symptoms can be subtle and initially mistaken for multiple sclerosis relapse, the date of diagnosis by MRI and CSF analysis is often the trigger for the limitations period. Patients should consult with an attorney promptly to preserve their rights. Settlement considerations for affected patients depend on several factors, including the adequacy of warnings provided by the manufacturer. The Tysabri label includes a boxed warning about PML risk and requires monitoring and immediate discontinuation at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, particularly for patients with anti-JCV antibodies or those on long-term therapy. The TOUCH program mandates regular evaluations and reporting of PML cases to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Failure to follow these protocols could affect liability. The timeline between Tysabri exposure and documented harm is critical for both medical management and legal claims. Patients who develop PML may experience rapid neurological decline, and early diagnosis and discontinuation of Tysabri are essential to improve outcomes. However, even with prompt cessation, many patients suffer permanent disability or death. For settlement purposes, the severity of harm, duration of treatment, presence of risk factors, and compliance with monitoring guidelines are all relevant. Arizona courts may consider whether the manufacturer provided adequate warnings and whether the prescribing physician adhered to the TOUCH program requirements. In summary, Tysabri-associated PML is a serious, often devastating complication with well-defined risk factors and a clear mechanistic basis. Patients in Arizona who have been harmed should be aware of the two-year statute of limitations from discovery of the injury and should seek legal counsel to evaluate their claims. Settlement outcomes will depend on the specific facts of each case, including the adequacy of warnings and the timeline of exposure and diagnosis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Arizona?

In Arizona, the statute of limitations for personal injury actions generally is two years from the date the injury is discovered or reasonably should have been discovered. For product liability claims involving prescription drugs, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Tysabri caused their PML. Given that PML symptoms can be subtle and initially mistaken for multiple sclerosis relapse, the date of diagnosis by MRI and CSF analysis is often the trigger for the limitations period. Patients should consult with an attorney promptly to preserve their rights.

What factors increase the risk of PML in Tysabri patients?

Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.